Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Onconetix ( (ONCO) ) has issued an announcement.
On February 24, 2025, Onconetix, Inc. announced significant changes in its executive leadership and board composition. Dr. Ralph Schiess resigned as Interim CEO and Chief Science Officer, while James Sapirstein, a seasoned leader with extensive experience in the pharmaceutical industry, was appointed as Executive Chairman. Additionally, Andrew Oakley joined the board as a new director. These changes are expected to influence Onconetix’s strategic direction and governance structure, potentially impacting its market positioning and stakeholder relations.
More about Onconetix
YTD Price Performance: -52.92%
Average Trading Volume: 9,166,304
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.46M
For a thorough assessment of ONCO stock, go to TipRanks’ Stock Analysis page.